bluuebunny/crossref_metadata_2025_split huggingface dataset:
The Self-Assessment of Resilience and Anxiety: Psychometric Properties
Authors: Barnett Stewart D. , Connor Kathryn M. , Davidson Jonathan R.T. 
Published: August 2016

ABSTRACTThis report describes the psychometric properties of the Self-Assessment of Resilience and Anxiety (SARA) scale within the context of a study of kava for generalized anxiety. This eight-item, patient-rated scale includes questions designed to measure calmness, mental clarity, confidence, physical well being, sociability, and resilience. The SARA scale was administered during a clinical trial of kava versus placebo in 38 subjects diagnosed with generalized anxiety disorder (GAD). Validation of the SARA scale was assessed against the Hamilton Rating Scale for Anxiety, Hospital Anxiety and Depression Scale, Penn State Worry Questionnaire, Sheehan Disability Scale, Arizona Sexual Experience scale, and Clinical Global Impression of Illness Improvement scale. Good test-retest reliability, internal consistency, convergent validity, and sensitivity to treatment were identified, and factor analyses revealed a three-factor internal structure. The SARA scale was responsive to symptom change over time and correlated with comparable GAD symptom measures. The SARA scale demonstrates solid psychometric properties and may serve as a reliable and valid measure in the use of kava or related medicinal herbs.
Panic and Agoraphobia: Gender as a Factor
Authors: Yonkers Kimberly A. 
Published: August 2016

Anxiety is a common experience, particularly as a response to life stressors. However, severe and uncontrollable anxiety can become a mental disorder. Community studies indicate that 19% of men and 31% of women will develop some type of anxiety disorder during their lifetime. In one such study, the National Comorbidity Survey (NCS), risk factors associated with a lifetime of anxiety disorder included lower income, less education, living in the northeast, and being female. The impact of patient sex is profound in that it increases the likelihood of developing an anxiety disorder by 85% in women compared to men.Panic disorder is characterized by brief but intense recurrent episodes of fear or discomfort. Diagnostic criteria require recurrent panic attacks in 1 month or one panic attack with continuous fear of other attacks. Symptoms associated with the panic attack include palpitations; sweating; feeling short of breath or a choking sensation; nausea or abdominal discomfort; feeling dizzy; having a sense of unreality; numbness or tingling; chills or hot flushes; and a fear of dying or losing control.
Heart Disease in Women
Authors: Davidson Karina W. 
Published: August 2016

Coronary heart disease (CHD) remains the leading cause of death in women in the United States and other industrial countries. CHD accounts for 250,000 female deaths per year, and in contrast to men, there is no indication of declining death rates. Women <65 years of age are twice as likely to die from myocardial infarction (MI) as men and have a poorer prognosis if they survive. Nevertheless, CHD has long been considered a “male” disease and many of the guidelines for prevention, diagnosis, and treatment of CHD are extrapolated from data of predominantly middle-aged men to women. It was only in the early 1990s that the National Institute of Health required that researchers report outcome analyses separately by sex. Since then, data has emerged showing that the magnitude of risk conferred by traditional risk factors for CHD (eg, hypertension, diabetes, and smoking) differs between men and women. Sex differences in molecular and cellular mechanisms, and genetics as well as responses to treatment are still vastly understudied.Increasing evidence suggests that besides traditional CHD risk factors, negative emotions are independent prognostic risk factors for CHD. Recently published guidelines by an expert panel for cardiovascular disease prevention in women mention depression as a target for potential psychosocial interventions. Anxiety has also been shown to predict CHD incidence, acute coronary syndromes (ACS), morbidity and mortality post-ACS, and sudden cardiac death. Studies on the relationship between anxiety and CHD have shown mixed results.
OCD in Women: Diagnosis and Magnitude
Authors: Pigott Teresa A. 
Published: August 2016

KeyDiagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for obsessive-compulsive disorder (OCD) include the presence of either obsessions or compulsions, some recognition by the individual that their symptoms are excessive or irrational (except in children), duration of at least 1 hour/day, and association with marked distress or functional impairment. OCD patients report that somatic, religious, and sexual obsessions as well as those concerning contamination, aggression, symmetry, and hoarding are most common. The most frequent compulsions reported in OCD patients involve checking, cleaning, counting, repeating, and hoarding behaviors. Factor analyses of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) symptom checklist have also identified five primary symptom dimensions: aggression/checking; contamination/cleaning; symmetry/repeating, counting, or ordering rituals; hoarding; and a sexual/religious symptom dimension.Results from a large, 2-year prospective study suggest that symptoms of adult OCD are much more stable than previously thought, with any changes more likely to occur within, rather than between the symptom dimensions. Prevalence estimates based on the Epidemiologic Catchment Area survey and the Cross-National OCD Collaborative Group study indicate a worldwide lifetime prevalence rate for OCD of 2% to 3%. Females have a slightly higher risk (1.5 times) for OCD (Slide I). OCD onset is relatively early, generally during adolescence or young adulthood. The clinical course of OCD is generally chronic and complicated by comorbidities.
CRHR1 Antagonists as Novel Treatment Strategies
Authors: Holsboer Florian 
Published: August 2016

AbstractResearch has provided considerable evidence for the hypothesis that corticotropin-releasing hormone (CRH), the key central coordinator of stress-hormone homeostasis, also plays a role in the development and course of depression and anxiety disorders. Studies using animal models of anxiety, as well as mouse mutants, in which the gene coding for the CRH type 1 receptor (CRHR1) was genetically deleted supported the notion that enhanced CRH/CRHR1 signaling underlies depression and anxiety disorders. Therefore, a number of small nonpeptide molecules that antagonize CRHR1 have been developed. In animal models, these molecules had anxiolytic and other stress-alleviating effects. An initial clinical study showed that CRHR1 antagonism has beneficial effects on depression and anxiety symptoms at doses unharmful to neuroendocrine stress responsivity.
In Search of Animal Models for Obsessive-Compulsive Disorder
Authors: Dodman Nicholas H. , Olivier Berend 
Published: August 2016

AbstractAnimal models of obsessive-compulsive disorder may be derived naturally or generated experimentally. Either may be considered a full or partial model, depending on the extent of resemblance to human OCD. Although many models appear to be valid at first glance, complete models should demonstrate “compelling similarities” in all areas examined. Partial models may have only one or two OCD-like features; however, they still provide some opportunities for research. Criteria to consider when evaluating potential models are etiology, symptomatology, and use in indicating methods of therapy and prevention. Demonstration of common underlying physiological mechanisms, patterns of development and expression, and familial associations are some specific elements to consider when assessing the relevance of more complete models.Cognitive aspects of OCD are difficult, if not impossible, to explore in animals at present and may be quite different from what is found in humans. It is hard to imagine that animals experience ego-dystonicity; however, dogs with acral lick dermatitis (ALD) that have been scolded by their owners will resort to licking themselves when out of sight, implying that they know it is wrong. Because of the difficulty in evaluating an animal's internal state, some adopt the position that there is no complete animal model of OCD and that animal models are at best partial models. However, children who exhibit compulsive behaviors frequently do not experience accompanying obsessions. Even the expression of OCD in children—for example, licking and walking in geometric designs—resembles what is seen in animals.In the descriptions that follow, only directly comparable aspects of compulsive behavior in animals will be discussed. Naturally occurring models that appear to correspond most closely to full models may be useful in understanding the fundamental mechanisms underlying OCD and the OC spectrum, including genetics and neurobiology. Experimental models, which may be either full or partial models, could contribute similarly or provide limited but specific information in a targeted area of study, depending on the extent of their similarity to OCD.
The Neuroanatomy of Serotonin (5-HT) Dysregulation in Obsessive-Compulsive Disorder
Authors: Grove Gregory , Coplan Jeremy , Margolin Lisa , Hollander Eric 
Published: August 2016

AbstractA growing body of evidence suggests that obsessive-compulsive disorder (OCD) may be associated with alterations of the serotonin (5-HT) system and that the dorsal raphe nucleus (DRN) may play a role in OCD. In this report, we review this evidence and explore the possible roles of 5-HT and DRN as they relate to OCD.
Treatment Guidelines for Acute Manic and Mixed Episodes of Bipolar Disorder
Authors: Frye Mark A. 
Published: August 2016

Bipolar disorder is a lifelong condition, and pharmacotherapy is essential to its long-term management. Once a comprehensive diagnostic assessment for acute or mixed mania has been completed, it is important to look at an evidence-based data set to guide treatment selection for mood stabilization.For most patients, lifetime adherence to pharmacotherapy is necessary for maximal mood stability. Pharmacotherapy is the primary treatment for bipolar disorder, as it has been found to be efficacious in treating acute episodes and preventing future episodes of bipolar I disorder. Combination therapy, including at least one mood stabilizer, may be necessary to treat acute depression and mania and to further prevent both depressive and manic recurrences. The goal is to minimize frequency, duration, and severity of depressive and manic symptoms with a treatment regimen, ideally a combination of pharmacotherapy and psychotherapy, that is positioned to maximize treatment adherence and minimize side effects.This discussion reviews some treatment guidelines for acute manic and mixed episodes associated with bipolar I disorder. Through the context of a case study, this discussion will attempt to provide an understanding and appreciation of Food and Drug Administration-approved and non-FDA-approved treatments for acute mania. In addition, the impact of alcohol as an example of drugs of abuse and its impact on the presentation of acute mania will be discussed.
The Neuropsychiatry of Autism and Asperger's Disorder: Review of the Literature and Case Reports
Authors: Aronowitz Bonnie R. , Decaria Concetta , Allen Andrea , Weiss Nicola , Saunders Audrey , Margolin Lisa , Mosovich Serge , Baum Montebuchs , Hollander Eric 
Published: August 2016

AbstractThe literature on neuropsychiatric, neuropsychological, and neuroimaging findings in autism and Asperger's disorder is briefly reviewed. Neurological soft sign, neuropsychological, and positron-emission tomography findings in one patient with Asperger's disorder and one patient with autism are highlighted, discussed as examples of heterogeneity, and integrated with the relevant literature.
Cognitive Dysfunction in Schizophrenia: Maze-Solving Behavior in Treated and Untreated Patients
Authors: Gallhofer B. , Krieger S. , Lis S. , Hargarter L. , Roder C. , Lammers C. , Meyer-Lindenberg A. 
Published: August 2016

AbstractIn this article, we present data on the analysis of maze-solving behavior as a tool for the investigation of cognitive disturbance in schizophrenic patients. Solving maze tasks efficiently requires both an interaction between and an integration of perceptive and action-oriented processes. Starting from the hypothesis that these domains are preferentially disturbed in schizophrenia, we propose that the maze-solving behavior of schizophrenic patients permits insight into specific impairments in disease-related cognitive processing. We present the results of a maze task study comparing medication-free schizophrenic patients and matched healthy controls. This analysis forms the basis for an investigation of the influence of psychopharmacological treatment strategies on the observed behavior in the maze-solving paradigm. Finally, a third study concerned with improvement over time associated with medication is presented, and possible influences of extrapyramidal motor disturbances on schizophrenic patients' maze performance are discussed.
Autism Screening and Diagnostic Evaluation: CAN Consensus Statement
Authors:   CAN Consensus Group
Published: August 2016

AbstractAutism and related disorders occur in as many as one in 500 children. Recognizing the need for uniform recommendations to help guide the initial diagnostic evaluation and referrals in this area, an initial working group of the Cure Autism Now Foundation promulgated the following consensus guidelines for autism screening and diagnostic referral. Although these recommendations were formulated using the best information currently available, they are likely to be modified as the results of additional studies become available; however, they provide a useful tool for clinicians involved in the management of children with autism and related developmental abnormalities.
Challenges in the Classification and Treatment of Trichotillomania
Authors: Ninan Philip T. , Mansueto Charles , Rothbaum Barbara O. , O'Sullivan Richard L. , Nemeroff Charles B. 
Published: August 2016

AbstractThe behavioral syndrome of trichotillomania (TTM) is well characterized, but challenges pertaining to TTM remain in several areas, including diagnostic classification, assessment of severity, and determination of relevance of comorbid psychiatric disorders. Acute pharmacological studies have focused on serotonin transport inhibitors, and preliminary evidence suggests that inhibition of both serotonin and norepinephrine transporters (ie, by clomipramine and venlafaxine) provides a clinical improvement. Dopamine antagonists are promising agents in need of systematic evaluation in TTM. Cognitive-behavioral therapy appears to achieve a decrease in acute symptoms in many patients. However, longitudinal maintenance of benefits has not been rigorously tested with either pharmacological or behavioral therapy. Clinical impressions and treatment data indicate that achieving durability of treatment benefits remains a major challenge in many patients with TTM, although there is evidence of improved outcome with comprehensive multimodal treatment.
The Effect of Risperidone on Cognitive and Psychopathological Manifestations of Schizophrenia
Authors: Lussier Isabelle , Stip Emmanuel 
Published: August 2016

AbstractThe purpose of this study was to evaluate the effect of risperidone on the cognitive functioning of patients with schizophrenia and how it relates to the alleviation of psychopathological symptoms usually observed in patients receiving treatment. Twelve schizophrenic patients were evaluated while being treated with a traditional neuroleptic, and again approximately 8 and 24 weeks after initiation of risperidone. Patients were compared with a group of normal controls (n=24) who underwent the same cognitive evaluation across time. The normal control group was included to evaluate the level of impairments in patients, but also to test for practice effects. The cognitive evaluation included measures of short-term and long-term memory; attention (alertness, sustained and selective); and executive functioning (verbal and category fluency). Clinical symptoms were rated on the Positive and Negative Symptoms Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS). Extrapyramidal symptoms were rated with the Extrapyramidal Symptoms Rating Scale.During treatment with risperidone, schizophrenic patients improved their BPRS and PANSS scores, their performance level on tests of alertness, and both sustained and selective attention.
WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder
Authors: Allgulander Christer , Bandelow Borwin , Hollander Eric , Montgomery Stuart A. , Nutt David J. , Okasha Ahmed , Pollack Mark H. , Stein Dan J. , Swinson Richard P. 
Published: August 2016

ABSTRACTWhat are the current recommendations for the long-term treatment of generalized anxiety disorder (GAD)? GAD is a common disorder with a lifetime prevalence of 4% to 7% in the general population. GAD is characterized by excessive, uncontrollable worry or anxiety about a number of events or activities that the individual experiences on more days than not over a 6-month period. Onset of GAD symptoms usually occurs during an individual's early twenties; however, high rates of GAD have also been seen in children and adolescents. The clinical course of GAD is often chronic, with 40% of patients reporting illness lasting >5 years. GAD is associated with pronounced functional impairment, resulting in decreased vocational function and reduced quality of life. Patients with GAD tend to be high users of outpatient medical care, which contributes significantly to healtcare costs. Currently, benzodiazepines and buspirone are prescribed frequently to treat GAD. Although both show efficacy in acute treatment trials, few long-term studies have been perform Benzodiazepines are not recommended for long-term treatment of GAD, due to associated development of tolerance, psychomotor impairment, cognitive and memory changes, physical dependence, and a withdrawal reaction on discontinuation. The antidepressant venlafaxine extended-release (XR) has received approval for the treatment of GAD in the United States and many other countries. Venlafaxine XR has demonstrated efficacy over placebo in two randomized treatment trials of 6 months' duration as well as in other acute trials. Paroxetine is the first of the selective serotonin reuptake inhibitors (SSRIs) to receive US approval for the treatment of GAD. Paroxetine demonstrated superiority to placebo in short-term trials, and investigations into the use of other SSRIs are ongoing. This suggests that other SSRIs, and serotonin and noradrenaline reuptake inhibitors, are likely to be effective in the treatment of GAD. Of the psychological therapies, cognitive-behavioral therapy (CBT) shows the greatest benefit in treating GAD patients. Treatment gains after a 12-week course of CBT may be maintained for up to 1 year. Currently, no guidelines exist for the long-term treatment of GAD.
A Consensus Meeting on Effective Research Practice in PTSD
Authors: Charney Dennis S. , Davidson Jonathan R.T. , Friedman Matthew , Judge Rajinder , Keane Terry , McFarlane Sandy , Martenyi Ferenc , Mellman Thomas A. , Petty Frederick , Plewes John , Putnam Frank , Romano Steve , Van der Kolk Bessel A. , Yehuda Rachel , Zohar Joseph 
Published: August 2016

AbstractThe aim of this meeting was to obtain a consensus on what constitutes good research practice in posttraumatic stress disorder (PTSD). Objectives were to review relevant parameters of trials, such as the patients recruited, the means of assessing PTSD at baseline, and the change in symptomatology in response to treatment, and to reach a consensus on the most appropriate parameters to use in future research. The bases for the discussion were the 1995 National Institute of Mental Health (NIMH) and the National Center for PTSD consensus on the assessment of PTSD, results of drug treatment trials, and information on the assessment scales used in PTSD research.
Current Diagnostic Issues and Epidemiological Insights in PTSD
Authors: Zohar Joseph , Sasson Yehuda , Amital Daniella , Iancu Iulian , Zinger Yaffa 
Published: August 2016

Posttraumatic stress disorder (PTSD) was associated in the past mainly with combatrelated events. This was reflected in the names given to the disorder, ie, “shell shock,” “soldier's heart,” “combat neurosis,” and “operational fatigue.” Only following the realization that PTSD can be related to all types of traumatic events, including noncombat associated events, were the terms “traumatic neurosis” and, later, “PTSD” coined. These new terms reflect the understanding that the condition need not necessarily be associated with war, but may also be related to events such as a severe automobile accident, violent personal assault (eg, rape, physical attack, robbery, or mugging), terrorist attack, natural or human-made disaster (such as a fire), witnessing serious injury or death due to any of the above, as well as to other situations, such as being kidnapped or being held hostage.The tendency to interpret the symptoms of what we would consider now as PTSD, as a “normal response” to traumatic events was another factor that held up progress in the field. It is important to note that PTSD is a pathological response: The vast majority of individuals who are exposed to a traumatic event will later adapt and continue on with their lives. Only a small percent, which partially depends on the type of trauma and is partially associated with several risk factors, will develop a pathological fixation on the traumatic event, namely, PTSD.It has been estimated that approximately one-third of the population will be exposed to a severe trauma (according to the definition of PTSD) during their lifetime.
HIV-1–Associated Cognitive-Motor Disorders: A Research-Based Approach to Diagnosis and Treatment
Authors: Goodkin Karl , Wilkie Frances. L. , Baldewicz Teri T. , Concha Mauricio , Tyll Mary D. , LoPiccolo Charles J. , Shapshak Paul 
Published: August 2016

AbstractThe diagnosis of human immunodeficiency virus type 1 (HIV-1)–associated cognitive-motor disorder—either minor cognitive-motor disorder (MCMD) or HIV-1-associated dementia (HAD)—is fraught with potential pitfalls for the clinician. Before making such a diagnosis, clinicians should exclude other etiologies by using neuroimaging, lumbar puncture, and serum chemistries to screen for opportunistic and non-opportunistic infections of the brain and meninges. Clinicians should also consider psychoneurotoxicity (caused from the use of psychoactive substances and prescribed medications) and psychopathology, such as mood, anxiety, and other disorders. In addition, a thorough medical history and physical examination, including a complete neurologic and neuropsychiatric mental status examination, are necessary for an accurate diagnosis. There is also a need for standardized neuropsychological and functional status tests, since the diagnostic criteria for these disorders are partly based on these criteria. Treatment targets should include subclinical cognitive-motor impairment and neuroprotection, as well as MCMD and HAD. Currently, zidovudine remains the best proven treatment for these disorders, but other nucleoside reverse transcriptase inhibitors, as well as nonnucleoside reverse transcriptase inhibitors and protease inhibitors, show promise, and selected agents from these classes are being tested in clinical trials. Other areas that should be investigated are the modulation of inflammatory mediators (such as tumor necrosis factor α), neurotransmitter manipulation (especially of dopamine), and nutritional interventions.